Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jameson

Showing results (251-260 of 262) with videos related to

Pageof 27
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2013
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox IIV J Harvey, K J Sharples, R J Isaacs, et al.
Chembiochem : a European Journal of Chemical Biology|October 22, 2019
Differential Inhibition of APOBEC3 DNA-Mutator Isozymes by Fluoro- and Non-Fluoro-Substituted 2'-Deoxyzebularine Embedded in Single-Stranded DNAMaksim V Kvach, Fareeda M Barzak, Stefan Harjes, et al.
Clinical Genitourinary Cancer|August 29, 2014
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trialReuben J Broom, Victoria Hinder, Katrina Sharples, et al.
Lancet (London, England)|March 19, 1983
Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemiaR L Powles, G R Morgenstern, H E Kay, et al.
Plos One|December 19, 2013
From knock-out phenotype to three-dimensional structure of a promising antibiotic target from Streptococcus pneumoniaeCon Dogovski, Michael A Gorman, Natalia E Ketaren, et al.
Structure (London, England : 1993)|July 19, 2016
Structural Determinants Defining the Allosteric Inhibition of an Essential Antibiotic TargetTatiana P Soares da Costa, Sebastien Desbois, Con Dogovski, et al.
Molecular Genetics and Genomics : MGG|July 29, 2003
Molecular analysis of two cytochrome P450 monooxygenase genes required for paxilline biosynthesis in Penicillium paxilli, and effects of paxilline intermediates on mammalian maxi-K ion channelsL K McMillan, R L Carr, C A Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
The Lancet. Oncology|July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialGeorgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.
Interventional Pain Medicine|June 15, 2026
Observations from the RESET clinical trial: A post-hoc per protocol analysis of clinical outcomes with percutaneous 60-day medial branch PNS in chronic low back painSean Li, Zachary L McCormick, Denise D Lester, et al.
Pageof 27

Showing results (251-260 of 262) with videos related to

Sort By:
Pageof 27
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2013
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox IIV J Harvey, K J Sharples, R J Isaacs, et al.
Chembiochem : a European Journal of Chemical Biology|October 22, 2019
Differential Inhibition of APOBEC3 DNA-Mutator Isozymes by Fluoro- and Non-Fluoro-Substituted 2'-Deoxyzebularine Embedded in Single-Stranded DNAMaksim V Kvach, Fareeda M Barzak, Stefan Harjes, et al.
Clinical Genitourinary Cancer|August 29, 2014
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trialReuben J Broom, Victoria Hinder, Katrina Sharples, et al.
Lancet (London, England)|March 19, 1983
Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemiaR L Powles, G R Morgenstern, H E Kay, et al.
Plos One|December 19, 2013
From knock-out phenotype to three-dimensional structure of a promising antibiotic target from Streptococcus pneumoniaeCon Dogovski, Michael A Gorman, Natalia E Ketaren, et al.
Structure (London, England : 1993)|July 19, 2016
Structural Determinants Defining the Allosteric Inhibition of an Essential Antibiotic TargetTatiana P Soares da Costa, Sebastien Desbois, Con Dogovski, et al.
Molecular Genetics and Genomics : MGG|July 29, 2003
Molecular analysis of two cytochrome P450 monooxygenase genes required for paxilline biosynthesis in Penicillium paxilli, and effects of paxilline intermediates on mammalian maxi-K ion channelsL K McMillan, R L Carr, C A Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
The Lancet. Oncology|July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialGeorgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.
Interventional Pain Medicine|June 15, 2026
Observations from the RESET clinical trial: A post-hoc per protocol analysis of clinical outcomes with percutaneous 60-day medial branch PNS in chronic low back painSean Li, Zachary L McCormick, Denise D Lester, et al.
Pageof 27